Alnylam Pharmaceuticals
ALNY
#635
Rank
C$45.09 B
Marketcap
$348.34
Share price
0.08%
Change (1 day)
74.29%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total liabilities

Total liabilities on the balance sheet as of December 2024 : C$6.00 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's total liabilities are C$6.00 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Alnylam Pharmaceuticals - Total liabilities on balance sheet (from 2003 to 2024)

Total liabilities by year

Year Total liabilities Change
2024-12-31C$5.98 B11.46%
2023-12-31C$5.37 B6.87%
2022-12-31C$5.02 B29.11%
2021-12-31C$3.89 B27.72%
2020-12-31C$3.04 B144.04%
2019-12-31C$1.24 B236.11%
2018-12-31C$0.37 B29.48%
2017-12-31C$0.28 B-37.66%
2016-12-31C$0.46 B172.49%
2015-12-31C$0.16 B1.58%
2014-12-31C$0.16 B4.04%
2013-12-31C$0.15 B4.76%
2012-12-31C$0.15 B-8.48%
2011-12-31C$0.16 B-29.03%
2010-12-31C$0.23 B-26.41%
2009-12-31C$0.31 B-25.52%
2008-12-31C$0.42 B45.85%
2007-12-31C$0.29 B550.08%
2006-12-31C$45.21 M6.19%
2005-12-31C$42.57 M77.55%
2004-12-31C$23.97 M-70.13%
2003-12-31C$80.28 M144.89%
2002-12-31C$32.78 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
C$1.37 B-77.05%๐Ÿ‡บ๐Ÿ‡ธ USA
C$12.10 B 101.44%๐Ÿ‡บ๐Ÿ‡ธ USA
C$3.50 B-41.64%๐Ÿ‡บ๐Ÿ‡ธ USA
C$1.20 B-80.00%๐Ÿ‡บ๐Ÿ‡ธ USA
C$10.01 M-99.83%๐Ÿ‡บ๐Ÿ‡ธ USA
C$83.67 B 1,292.80%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
C$82.31 B 1,270.09%๐Ÿ‡ซ๐Ÿ‡ท France
C$48.38 B 705.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel